Rhenman & Partners Asset Management’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Rhenman & Partners Asset Management’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-130,000	Closed	-$8.1M	–	97
2022 Q3	$8.1M	Sell	130,000 -195,299	-60%	-$13.6M	0.85%	47
2022 Q2	$25.9M	Sell	325,299 -10,538	-3%	-$998K	2.95%	10
2022 Q1	$35.3M	Sell	335,837 -89,163	-21%	-$8.69M	3.49%	2
2021 Q4	$46M	Sell	425,000 -45,000	-10%	-$4.91M	3.06%	4
2021 Q3	$51.5M	Sell	470,000 -55,000	-10%	-$5.71M	3.61%	1
2021 Q2	$49.2M	Sell	525,000 -70,000	-12%	-$6.44M	3.34%	2
2021 Q1	$54.8M	Sell	595,000 -5,000	-0.8%	-$422K	3.82%	1
2020 Q4	$43.9M	Sell	600,000 -95,000	-14%	-$7.06M	3.58%	3
2020 Q3	$54M	Sell	695,000 -55,000	-7%	-$3.78M	4.8%	2
2020 Q2	$41.7M	Sell	750,000 -250,000	-25%	-$10.7M	4.5%	1
2020 Q1	$29.6M	Buy	1,000,000 +225,000	+29%	+$7.61M	4.15%	1
2019 Q4	$28.1M	Sell	775,000 -250,000	-24%	-$7.67M	3.07%	4
2019 Q3	$27.9M	Buy	+1,025,000	New	+$26.5M	3.5%	2
2019 Q2	–	Sell	-939,973	Closed	-$24.8M	–	99
2019 Q1	$24.8M	Sell	939,973 -6,087	-0.6%	-$144K	2.91%	6
2018 Q4	$18.5M	Buy	946,060 +29,009	+3%	+$569K	2.11%	15
2018 Q3	$18M	Sell	917,051 -715,161	-44%	-$13.6M	1.8%	22
2018 Q2	$27M	Sell	1,632,212 -375,000	-19%	-$5.72M	2.77%	2
2018 Q1	$28.5M	Buy	2,007,212 +52,300	+3%	+$773K	3.51%	1
2017 Q4	$28.5M	Sell	1,954,912 -1,051,950	-35%	-$14.8M	3.86%	1
2017 Q3	$38.1M	Buy	3,006,862 +584,772	+24%	+$7.44M	4.87%	1
2017 Q2	$28.8M	Buy	2,422,090 +670,768	+38%	+$8.34M	4.13%	1
2017 Q1	$25.9M	Buy	1,751,322 +1,051,322	+150%	+$17M	4.1%	1
2016 Q4	$11.3M	Buy	700,000 +335,000	+92%	+$6.07M	2.17%	11
2016 Q3	$6.62M	Sell	365,000 -5,000	-1%	-$97.7K	1.05%	37
2016 Q2	$6.09M	Buy	370,000 +170,000	+85%	+$2.75M	1.08%	33
2016 Q1	$3.31M	Buy	200,000 +54,000	+37%	+$945K	0.66%	54
2015 Q4	$3.16M	Buy	+146,000	New	+$2.84M	0.48%	67

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Rhenman & Partners Asset Management's HZNP Position: Q4 2022 in Review

Rhenman & Partners Asset Management sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 130,000 shares — an estimated $8.1M sold.

Rhenman & Partners Asset Management first reported a position in HZNP in Q4 2015 and held it in 27 quarters. The position peaked at $54.8M in Q1 2021. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Rhenman & Partners Asset Management reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Rhenman & Partners Asset Management sold 130,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $8.1M.
Rhenman & Partners Asset Management first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q4 2015 and held it in 27 quarters.
Rhenman & Partners Asset Management's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $54.8M in Q1 2021.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2022, filed 13 Feb 2023.